Global Dendritic Cell Cancer Vaccines Market - 2020-2027
発行: DataM Intelligence
ページ情報: 英文 180 Pages
The global dendritic cell cancer vaccines market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).
Cancer treatment vaccines are made up of cancer cells, parts of cancer cells or antigens. These are made to recognize proteins on specific cancer cells. These cells help the immune system to recognize and attack those cancer cells. These vaccines might eventually help stop cancer growth, prevent cancer from coming back, and destroy cancer cells left behind after other treatments. Monocytes are extracted from the bloodstream of patients and cultured with synthetic forms of selected cancer neoantigens to form mature dendritic cells carrying those neoantigens. These cells are then reinfused into the patient's blood circulation. These dendritic cells help the immune system to recognize and attack abnormal cells, such as cancer cells. To make the vaccine, scientists grow dendritic cells alongside cancer cells in the lab. The vaccine then stimulates the immune system to attack cancer.
The growing incidence of cancer cases drives the global dendritic cell cancer vaccines market growth, increasing demand for therapies, improving technology such as drug innovations regarding cancer, upsurge in awareness about cancer and their available therapies, and increasing health care expenditure drive the market.
Growing incidence of cancer cases globally, is expected to drive the global Dendritic Cell Cancer Vaccines market growth.
As per the World Health Organization (WHO), Cancer is the second-most leading cause of death worldwide, accounting for over 18.1 million cases were diagnosed in 2018. In 2020, around 19 Mn new cancer cases were diagnosed across the world as per the WHO. Likewise, the American Cancer Society reported that 89,500 cases were diagnosed in the U.S. in 2020. Additionally, according to International Agency for Research on Cancer (IARC) estimates, by 2040, global cancer cases are expected to grow to 27.5 million new cancer cases worldwide. This number has led to an increase in the adoption of various cancer vaccines.
Stringent regulatory procedures are likely restricting the market growth.
As the increase in innovative strategies with novel products, a 2-way dialog with regulators is recommended on a case-by-case basis to justify the clinical development plan, taking into account specific quality issues related to the product's development. The rationale, background and justification for the planned development must be convincing when interacting with the regulatory authorities to enable drug developers and regulators to reach an agreement.
COVID-19 Impact Analysis
The COVID-19 pandemic has negatively impacted healthcare systems globally and majorly on the Personalized Cancer Vaccines. As per the article published in Cancer Connect 2020, doctors from Dana Farber Cancer Institute determined that during the COVID-19 pandemic, there was a 46% decrease in the diagnoses of the six most common cancer types - breast, colorectal, lung, pancreatic, gastric, and esophageal cancers. According to the Centers for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, be postponed unless the risks outweighed the benefits and secure the hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has impacted the On-going clinical trials too. However, the situation is expected to improve gradually.
Based on the Product Type, the global dendritic cell cancer vaccines market is segmented into Provenge (Sipuleucel-T), Apceden, CreaVax and Others
Provenge (Sipuleucel-T) accounts the largest share of the market.
Provenge (Sipuleucel-T) is a first approved dendritic cell cancer vaccine used to treat metastatic prostate cancer. It is used in patients with few or no symptoms and whose cancer is castration-resistant. It is made from a patient's immune cells that have been treated in the laboratory with GM-CSF (a type of growth factor) and a protein found on prostate cancer cells. Sipuleucel-T helps the immune system to kill prostate cancer cells, is a type of cellular adoptive immunotherapy. Also called APC8015 and Provenge. For instance, Sipuleucel-T was approved by the FDA on April 29, 2010, for the treatment of asymptomatic or less symptomatic metastatic castrate-resistant prostate cancer developed by Dendreon Corporation.
Based on End-users, the global Dendritic Cell Cancer Vaccines market is segmented into Pediatrics, Adults and Others
Dendritic cell vaccine treatment has been performed targeting many different types of tumor entities, most of which belong to types of cancer typically occurring in adults like melanoma, renal cell carcinoma, breast, colon, and prostate cancer, and Malignant glioma has also gained considerable attention in the field. This tumor is a tumor entity relevant also in pediatric oncology.
North America region holds the largest market share global Dendritic Cell Cancer Vaccines market
North America holds the largest market in the global cancer stem cells market due to the high incidence of cancer, according to the International Agency for Research on Cancer (IARC), which claims 13 million new cancer cases worldwide. The World Cancer Report provides that the incidence rate of new cancer cases is increased by 50% to 15 million in 2020. The existence of a highly developed healthcare system, the high degree of acceptance by medical practitioners of novel chemotherapy and immunotherapy methods, the total availability of advanced technological tools, FDA approval of new drugs and also the presence of a vast number of organizations engaged in R&D activities related to cancer vaccines.
The Asia Pacific is expected to be the fastest-growing market over the forecast period owing to increasing prevalence rate, increasing focus on preventive care, and government initiatives promoting technological innovations. For instance, Capital Medical University Collaborated with Duke University conducting early Phase 1 study on personalized vaccine generated by Autologous Dendritic Cells Pulsed with Autologous Whole Tumor Cell Lysate to treat Advanced Solid Tumor Patients.
The Global Dendritic Cell Cancer Vaccines Market is quite competitive with some key competitors like 3M Company, Activarti, Argos Therapeutics, Bellicum Pharmaceuticals, Dendreon Corporation, Elios Therapeutics. ImmunoCellular Therapeutics, Medigene, Merck & co, Northwest Biotherapeutics. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, contributing to the market's growth globally. For instance, On June 2, 2020, Northwest Biotherapeutics Inc, developed DCVax personalized immune therapy for solid tumor cancers is under Phase I/II trial of DCVax-Direct for all types of inoperable solid tumors.
Overview: Dendreon is a biotechnology company headquartered in California. Its lead product, Provenge, known generically as sipuleucel-T, is immunotherapy for prostate cancer and consists of a mixture of the patient's blood cells (autologous, with dendritic cells thought to be the most important) that have been incubated with the Dendreon PAP-GM-CSF fusion protein. In 2017, Dendreon resumed operations as a standalone company following an acquisition by Sanpower Group for $819.9 million.
Product Portfolio: Dendreon aims to stay at the forefront of development, manufacturing, and commercialization of immunotherapies that harness the power of the body's immune system to help extend patients' lives.
Key developments: P11-3 (STAMP)- A randomized, open-label, Phase 2 Trial of sipuleucel-T with concurrent versus sequential administration of abiraterone acetate plus prednisone in men with metastatic castrate resistant prostate cancer (mCRPC).
The global Dendritic Cell Cancer Vaccines Market report would provide an access to an approx. 53 market data table, 43 figures and 240 pages.
LIST NOT EXHAUSTIVE